Photobiomodulation on Recovery in Female Futsal Athletes (PBMT)

March 30, 2026 updated by: Andreo Fernando Aguiar, Universidade Norte do Paraná

Effects of Photobiomodulation Therapy on Recovery After Exercise in Female Futsal Athletes

The aim of this study is to investigate the effects of photobiomodulation therapy (PBMT) on recovery after high-intensity, intermittent exercises in female futsal athletes. It is hypothesized that PBMT is superior to placebo condition in improving the recovery of muscle function after high-intensity, intermittent exercises.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The aim of this project is to investigate the effects of photobiomodulation therapy (PBMT) on recovery of muscle function after high-intensity, intermittent exercises in female futsal athletes. A crossover experimental studies will be conducted with 15 female futsal athletes. Participants will undergo two consecutive blocks (B1 and B2) involving the Bangsbo sprint test (BST) and the yoyo intermittent recovery level-1 (YYIR1) at two time points (M1 and M2), separated by a 2-week washout period. PBMT will be applied in the 10-minute interval between blocks B1 and B2. PBMT will be applied according to the randomization order at M1 and M2, so that the participant who receives active PBMT at M1 will receive placebo PBMT at M2, and vice versa. The following variables will be analyzed in the BST: (1) Best Time: the shortest time obtained in the sprints, (2) Total Time (TT): the sum of the time of all sprints, and (4) Fatigue Index (FI): the difference between the worst and best times. For the yo-yo test, the total distance covered will be analyzed as an indicator of aerobic performance. In addition, the rating of perceived exertion (RPE) will be measured immediately after each test in blocks B1 and B2.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
15

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Women aged 18-35 years
  • Be a futsal athlete for at least 2 years

Exclusion Criteria:

  • Users of tobacco products
  • Use of nutritional supplements or anabolic steroid hormones for at least 6 months prior to the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Active PBMT
Participants will receive the active Photobiomodulation
Device: Active PBMT
Participants will receive the active Photobiomodulation
Placebo Comparator: Placebo PBMT
Participants will receive the placebo Photobiomodulation
Device: Placebo PBMT
Participants will receive the placebo Photobiomodulation

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Physical performance in the Bangsbo Sprint Test
Time Frame: Baseline (M1) and after 2 weeks (M2)
The ability to perform repeated sprints with changes of direction will be assessed using the Bangsbo sprint test (BST). The test consists of seven sprints of 34.2 meters between the starting cone (A) and the finishing cone (E), interspersed with a 25-second active recovery period. During recovery, participants perform a light jog back to the starting point (cone A). The change of direction (right or left) between cones B and C in the first sprint is determined by each participant's individual preference, and subsequent sprints are performed alternately between the right and left sides. Participants will be verbally encouraged to perform their best in all sprints. The following variables were analyzed: total time (sum of all sprints), and fatigue index (FI) = 100 - (average time/best time) x 100). The BST is considered valid and reliable for analyzing aerobic recovery capacity.
Baseline (M1) and after 2 weeks (M2)
Performance in Yoyo intermittent recovery level 1
Time Frame: Baseline (M1) and after 2 weeks (M2)
Aerobic recovery capacity in high-intensity intermittent running will be assessed using the yo-yo intermittent recovery test level 1 (YYIR1). The protocol consists of 40-meter runs (stages) between cones B and C (20 m out + 20 m back) followed by 10 seconds of active recovery between cones A and B (walking a 5 m path). The initial speed of the test is 10 km/h, with a progressive increase in speed by auditory stimulus (beeps) (the time between "beeps" decreases at each stage, forcing the athlete to run faster). The test is terminated when the participant does not reach the marking line (cone B) within the stipulated time in two attempts (even if not consecutive) or is unable to continue the test due to fatigue/exhaustion (6). Participants are verbally encouraged to perform as well as possible during the test. The total distance covered (in meters) will be used as a variable for aerobic performance. The YYIR1 test is considered valid and reliable for analyzing aerobic recovery capacity.
Baseline (M1) and after 2 weeks (M2)
Rating of perceived exertion (RPE)
Time Frame: Baseline (M1) and after 2 weeks (M2)
The RPE will be recorded immediately after the Bangsbo and YYIR1 tests, using the Borg 6-20 scale. The scale contains 15 points ranging from 6 "no effort" to 20 "maximum effort", and the participant indicate a number on the scale that represent their perceived exertion at that moment. RPE is a simple, valid and reliable instrument for assessing perceived exertion in running tests. All participants will be previously familiarized with the scale through the cognitive anchoring procedure.
Baseline (M1) and after 2 weeks (M2)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Universidade Norte do Paraná

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 15, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 10, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 30, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 30, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 6, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 6, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 30, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Study 2 - PBMT and recovery

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings